drugset / Trial / NCT05937152
A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
RandomizedSequentialDouble-blindTreatment
Summary
The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).
Timeline
- Start
- 2025-01
- Primary completion
- 2025-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptinezumab | Monoclonal antibody | 300 mg | Intravenous |